Amgen Inc. (NASDAQ:AMGN) is included among the 13 Best NASDAQ Dividend Stocks to Buy Now. On February 20, Barclays initiated coverage of Amgen Inc. (NASDAQ:AMGN) with an Equal Weight rating and a $185 ...

At Amgen, science and purpose go hand in hand. The company’s mission, which is to serve patients, is at the heart of everything it does. The company harnesses the best of biology and technology to ...

Amgen’s (AMGN) decade-long commitment to shareholder value is underscored by a staggering $86 billion capital return program, a feat that firmly establishes the biotech giant as a premier player in ...

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said Tuesday as it presented quarterly financial results. Amgen explained that ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus ...

US market availability for Tavneos continues as Amgen works with the FDA to address concerns over trial data assessment and known hepatotoxicity risks. Amgen is providing prescribers with updated ...

Amgen's Q4 results beat expectations, shares rise modestly MariTide seen as a paradigm-changing weight-loss drug Amgen's 2026 earnings forecast suggests modest upside, says Citi analyst Feb 3 (Reuters ...

Amgen (NASDAQ:AMGN) is preparing to release its quarterly earnings on Tuesday, 2026-02-03. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Amgen ...

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.

Just over one year ago I covered the California-based Pharma Amgen Inc.'s (AMGN) Q4 and full-year 2024 earnings in a note for Seeking Alpha, assigning stock a Hold rating. Shares have risen in value ...

Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more. Got a confidential news tip? We want to ...